Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Ex Input:
"I'd love to be in the bush, but I get more cases here," said veterinary rehabilitation specialist Nicci Wright. Wright founded the hospital two years ago with veterinarian Dr. Karin Lourens and since then has treated about 4,000 animals. With the expansion of Pretoria and Johannesburg, South Africa's capital city and its economic center, the animals indigenous to the region are being squeezed out by the rapid urbanization. The wildlife hospital mainly treats small mammals and raptors that are injured. There are about 160 animals on the small premises now, including half a dozen leopard tortoises, a toothless 12-foot python and an otter that was taken far from her natural habitat when someone tried to domesticate her as a pet. A Johannesburg resident arrives at the hospital, carrying a gray lourie in a cage made for much smaller domesticated bird. He found the large bird in the garden, attacked by his dogs, unable to fly after its tail and wing feathers were plucked out. Like in any hospital, nurse Alicia Abbott opens a file and transfers the new patient to a more comfortable setting so its treatment may begin. Most of the cages in the hospital are covered with towels to block the electric light from disturbing the animals. Along with physical injuries, many of them also suffer from trauma. Some species, like the endangered pangolin, show visible signs of post-traumatic stress disorder when they hear a male human voice or smell cigarettes smoke, a reminder of the poachers who hunt them, said Wright. "Everything is terrifying for them," she said. In a wooden crate on the hospital floor, a juvenile pangolin begins to stir, scratching against the box. It is feeding time and a volunteer will walk him on a nearby hill where the pangolin, which is a scaly anteater, animal to search for ants. Pangolins are one of the world's most heavily trafficked mammals because of demand for their scales in Asia. Another pangolin was recently sedated and checked by a sonogram scan to find that she was pregnant. Along with five staffers, the hospital relies on volunteers like Lauren Beckley, who lives nearby. Beckley cares for young primates like baboons and vervet monkeys, who cling to her after their own mothers have been shot or run over by humans. Other wildlife at the hospital include two newly born bush babies which are small nocturnal primates. One had been attacked by a cat and the other had fallen out of its nest. Once the animals are ready to return to the bush, Wright and her team work with nature reserves around the country to slowly introduce the animals into a new, safer, habitat.

Ex Output:
Johannesburg wildlife clinic saves animals hurt in city.

Ex Input:
Evolocumab met the main goal of a late-stage trial titled RUTHERFORD-2 by lowering "bad" LDL cholesterol levels when tested against a placebo on 329 patients. Amgen, the world's biggest biotechnology company, is testing evolocumab widely on a variety of subpopulations. The RUTHERFORD-2 study included patients with familial hypercholesterolemia, an inherited condition that causes high levels of "bad" LDL cholesterol starting at birth. Specifically, patients in the study had heterozygous familial hypercholesterolemia, which is one of the most common genetic disorders affecting about one out of every 300 to 500 people worldwide, according to Amgen. The company on Tuesday reported positive results from a fourth late-stage study of evolocumab, for which it plans to begin seeking approvals this year. The drug is intended for people who cannot tolerate widely used statins, or who are unable to get their LDL levels low enough despite using high potency statins, such as AstraZeneca's Crestor. Amgen's shares closed at $120.89 on the Nasdaq on Thursday.

Ex Output:
Amgen's cholesterol fighter succeeds in fifth late-stage study.

Ex Input:
"The cost of the drug wasn't mentioned a big oversight. Other news stories pegged it at about $35,000 a year. Adequate job. The story explained: ""But experts stress that Benlysta is not a miracle drug: It only worked in 35 percent of North American patients tested and was not effective for patients with the deadliest form of the disease. Additionally, it did not show positive results in African Americans, who are disproportionately affected by lupus."" There was no discussion of harms. An NPR story, by comparison, pointed out that ""There are side effects, of course, and some of them are pretty serious. In clinical tests involving about 2,100 people, 11 taking Benlysta died compared with 4 getting placebo. About 6 percent of people taking Benlysta got serious infections compared with 5.2 percent on placebo."" The story offered an interesting historical perspective on the evidence: ""The company originally tested Benlysta, known generically as belimumab, as a treatment for rheumatoid arthritis. When a mid-stage trial in lupus patients failed to meet researchers' goals in 2006, many analysts wrote the drug off and downgraded the company's stock. But when scientists reanalyzed the data they found that the drug helped block the antibodies that cause lupus symptoms in a subset of patients."" No disease mongering of lupus. Two independent sources were quoted. Not applicable. With no other new drug approved for lupus in 56 years, there's not been much to compare it with. The story did state that some experts thought this ""could prompt development of other drugs that are even more effective in treating the debilitating immune system disorder."" The focus of the story is FDA approval of the new drug. The headline explains that the FDA approved the first new drug for lupus in 56 years. It's clear the story did not rely solely on a news release."

Ex Output:
FDA approves first new drug for lupus in 56 years